Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FGFR2
Variant G227E
Impact List missense
Protein Effect unknown
Gene Variant Descriptions FGFR2 G227E lies within the Ig-like C2-type 2 domain of the Fgfr2 protein (UniProt.org). The functional effect of G227E is conflicting, as it has been reported to impair receptor processing and trafficking to the cell membrane and reduce ligand-dependent cell proliferation in one study (PMID: 19147536), similar cell proliferation and viability levels to wild-type Fgfr2 in two different cell lines in another study (PMID: 29533785), and a growth advantage relative to wild-type Fgfr2 in a competition assay but transformation activity similar to wild-type Fgfr2 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown.
Associated Drug Resistance
Category Variants Paths

FGFR2 mutant FGFR2 G227E

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000141.5
gDNA chr10:g.121538660C>T
cDNA c.680G>A
Protein p.G227E
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001144915.2 chr10:g.121517455_121517456delGTinsAG c.680_681delGTinsAG p.G227E RefSeq GRCh38/hg38
NM_001320658.1 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001320658 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144917 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144919.1 chr10:g.121518822C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_000141.5 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_022970.4 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_022970.3 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_023029.2 chr10:g.121517455_121517456delGTinsAG c.680_681delGTinsAG p.G227E RefSeq GRCh38/hg38
NM_001144917.1 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_023029 chr10:g.121517455_121517456delACinsCT c.680_681delGTinsAG p.G227E RefSeq GRCh38/hg38
NM_001144919 chr10:g.121518822C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144914.1 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144915.1 chr10:g.121517455_121517456delGTinsAG c.680_681delGTinsAG p.G227E RefSeq GRCh38/hg38
NM_000141.4 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_000141 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144915 chr10:g.121517455_121517456delACinsCT c.680_681delGTinsAG p.G227E RefSeq GRCh38/hg38
NM_001144914 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144914.1 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_023029.2 chr10:g.121517455_121517456delGTinsAG c.680_681delGTinsAG p.G227E RefSeq GRCh38/hg38
NM_001320658.2 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144917.2 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144919.2 chr10:g.121518822C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_022970 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38
NM_001144913 chr10:g.121538660C>T c.680G>A p.G227E RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 G227E Advanced Solid Tumor predicted - sensitive Fexagratinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 G227E Advanced Solid Tumor predicted - sensitive Infigratinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 G227E Advanced Solid Tumor predicted - resistant Dovitinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 G227E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). 34272467
FGFR2 G227E Advanced Solid Tumor predicted - sensitive Erdafitinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 G227E Advanced Solid Tumor predicted - sensitive Futibatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 G227E Advanced Solid Tumor predicted - sensitive Pemigatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 G227E Advanced Solid Tumor predicted - sensitive E7090 Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 G227E were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467